| Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. | |
| | |
MedLine Citation:
|
PMID: 16541480 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate the longterm effects of the anti-tumor necrosis factor (TNF) therapy infliximab, a drug known to reduce disease activity in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). METHODS: Eighty-two patients (50 with RA, 32 with AS) aged 17-77 years were enrolled. All patients were treated with intravenous infliximab. Lipid profile was assessed at baseline and after 6 months of treatment. RESULTS: Disease activity significantly decreased in patients with RA and AS at the end of infliximab therapy. Infliximab treatment significantly increased total cholesterol from 206 to 216 mg/dl (p < 0.05) and triglycerides from 109 to 122 mg/dl (p < 0.05). The low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol did not change during treatment. Furthermore, the total cholesterol/HDL cholesterol and triglycerides/HDL cholesterol ratios did not change significantly. CONCLUSION: The influence of infliximab treatment on lipid profile seems to be neutral, since neither LDL cholesterol levels nor total cholesterol/HDL cholesterol and triglycerides/HDL cholesterol ratios changed significantly during the 6-month therapy. Our findings suggest that the favorable effect of infliximab treatment on cardiovascular comorbidity may not be mainly mediated by the effects on the lipid profile, but further investigations are needed in order to confirm this hypothesis. |
| | |
Authors:
|
Dimitrios N Kiortsis; Anastasios K Mavridis; Theodosios D Filippatos; Spyros Vasakos; Spyros N Nikas; Alexandros A Drosos |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2006-03-15 |
Journal Detail:
|
Title: The Journal of rheumatology Volume: 33 ISSN: 0315-162X ISO Abbreviation: J. Rheumatol. Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-05-02 Completed Date: 2006-08-09 Revised Date: 2006-09-12 |
Medline Journal Info:
|
Nlm Unique ID: 7501984 Medline TA: J Rheumatol Country: Canada |
Other Details:
|
Languages: eng Pagination: 921-3 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, and the Rheumatology Clinic, Medical School, University of Ioannina, Ioannina, Greece. dkiorts@cc.uio.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antibodies, Monoclonal / pharmacology, therapeutic use* Antirheumatic Agents / pharmacology, therapeutic use* Arthritis, Rheumatoid / blood*, drug therapy, physiopathology Cholesterol / blood Endothelium, Vascular / physiopathology Female Humans Lipoproteins / blood* Lipoproteins, HDL / blood Lipoproteins, LDL / blood Longitudinal Studies Male Middle Aged Spondylitis, Ankylosing / blood*, drug therapy, physiopathology Triglycerides / blood Tumor Necrosis Factor-alpha / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Lipoproteins; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Triglycerides; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treat...
Next Document: Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience...